Zegerid OTC (omeprazole / sodium bicarbonate) Disease Interactions
There are 4 disease interactions with Zegerid OTC (omeprazole / sodium bicarbonate):
Alkalinizing agents (Includes Zegerid OTC) ↔ sodium/water balance
Severe Potential Hazard, High plausibility. Applies to: Congestive Heart Failure, Fluid Retention, Hypernatremia
Alkalinizing agents containing sodium can induce sodium and water retention and result in hypernatremia, hypokalemia, hyperosmolality, edema and aggravation of congestive heart failure. Therapy with sodium- containing alkalinizing agents should not be used in patients with hypernatremia or fluid retention. Clinical monitoring of acid/base balance and electrolytes prior to, during, a following completion of therapy with alkalinizing agents is recommended.
- "Product Information. Sodium Bicarbonate (sodium bicarbonate)." Astra USA, Westborough, MA.
- "Product Information. Sodium Lactate (sodium lactate)." Abbott Pharmaceutical, Abbott Park, IL.
PPIs (Includes Zegerid OTC) ↔ C. diff
Severe Potential Hazard, Moderate plausibility. Applies to: Pseudomembranous Colitis, Diarrhea
Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients. This diagnosis should be considered for diarrhea that does not improve. It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated. Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents. Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C. difficile. C. difficile produces toxins A and B, which contribute to the development of CDAD. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.
Proton pump inhibitors (Includes Zegerid OTC) ↔ bone fractures
Moderate Potential Hazard, Moderate plausibility. Applies to: Osteoporosis
Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine. The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer). Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated. Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.
Proton pump inhibitors (Includes Zegerid OTC) ↔ hypomagnesemia
Moderate Potential Hazard, Moderate plausibility. Applies to: Magnesium Imbalance
Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy. Serious adverse events can include tetany, seizures, and arrhythmias. Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics). Regular monitoring is recommended.
Zegerid OTC (omeprazole / sodium bicarbonate) drug interactions
There are 552 drug interactions with Zegerid OTC (omeprazole / sodium bicarbonate)
More about Zegerid OTC (omeprazole / sodium bicarbonate)
- Zegerid OTC Side Effects
- During Pregnancy
- Dosage Information
- Drug Images
- Drug Interactions
- Pricing & Coupons
- En Español
- 5 Reviews
- Drug class: proton pump inhibitors
- FDA Alerts (3)
Related treatment guides
Drug Interaction Classification
|No information available.|
Do not stop taking any medications without consulting your healthcare provider.